New research suggests that individuals who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who end traditional diet and exercise regimens.
Published data in a leading health publication demonstrates that while overweight people frequently drop about a fifth of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments should be aware of the potential of fast weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to original mass in about a year and a half.
Analyzing Approaches
The study, which examined dozens of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who lose weight through diet and exercise generally have a slower weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Regain
Experts believe the way of the drugs explains the accelerated weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means appetite is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the therapy is often ongoing.
This view is echoed by pharmaceutical companies, who state that the results "highlight the persistent nature of excess weight," akin to managing diseases like diabetes.
User Accounts
Individuals who have stopped the jabs explain a powerful return of hunger.
"It was like a trigger activating and you're instantly starving," said an individual.
This challenge is exacerbated if users have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Adoption
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among females compared to males.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone fix and long-term success hinges on integrated behavioural support.
